secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001104659-24-112866
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon Q3 revenue $1.582B (+4% YoY); narrows FY revenue guidance upward to $6.375-6.425B
--------------------------------------------------------------------------------

- GAAP diluted EPS $1.38; non-GAAP adjusted diluted EPS $0.87 (includes $0.16 IPR&D charge).
- Women's Health +5% as-reported; Nexplanon grew 11% ex-FX; fertility +14% ex-FX.
- Biosimilars +16% as-reported; Hadlima launch drove uptake; Renflexis +4% ex-FX.
- FY2024 revenue midpoint raised $50M to $6.375-6.425B; Adj. EBITDA margin guide revised to 30-31%.
- Established Brands +2% as-reported; flat ex-FX growth expected for full year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465924112866/0001104659-24-112866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465924112866/tm2427187d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-112866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer